Traws Pharma Announces Management Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 28 2025
0mins
Source: Newsfilter
Leadership Change at Traws Pharma: Werner Cautreels, PhD, will retire as CEO of Traws Pharma on March 31, 2025, transitioning to a Board Member and special advisor role, while Iain D. Dukes, D Phil, will take over as Interim CEO.
Company's Focus and Future Plans: Traws Pharma is dedicated to developing novel antiviral therapies for respiratory viral diseases, with ongoing clinical programs targeting bird flu and COVID-19, and an Investor Update call scheduled for March 31, 2025.
Analyst Views on IOVA
Wall Street analysts forecast IOVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOVA is 6.50 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.220
Low
4.00
Averages
6.50
High
9.00
Current: 2.220
Low
4.00
Averages
6.50
High
9.00
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
